Compare · APDN vs RCM
APDN vs RCM
Side-by-side comparison of Applied DNA Sciences Inc. (APDN) and R1 RCM Inc. (RCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APDN and RCM operate in Other Consumer Services (Consumer Discretionary), so they compete in similar markets.
- RCM is the larger of the two at $6.21B, about 259.2x APDN ($24.0M).
- RCM has more recent analyst coverage (25 ratings vs 2 for APDN).
- Company
- Applied DNA Sciences Inc.
- R1 RCM Inc.
- Price
- $5.67+31.25%
- $14.32+0.07%
- Market cap
- $24.0M
- $6.21B
- 1M return
- +142.31%
- -
- 1Y return
- +2.53%
- -
- Industry
- Other Consumer Services
- Other Consumer Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 2
- 25
Applied DNA Sciences Inc.
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
R1 RCM Inc.
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services comprising physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Chicago, Illinois.
Latest APDN
- SEC Form DEFA14A filed by Applied DNA Sciences Inc.
- Applied DNA Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Applied DNA Sciences Inc.
- Applied DNA Sciences Inc. filed SEC Form 8-K: Leadership Update
- SEC Form DEF 14A filed by Applied DNA Sciences Inc.
- SEC Form 424B5 filed by Applied DNA Sciences Inc.
- Applied DNA Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form PRE 14A filed by Applied DNA Sciences Inc.
- SEC Form S-1 filed by Applied DNA Sciences Inc.
- Applied DNA Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest RCM
- Amendment: SEC Form SC 13D/A filed by R1 RCM Inc.
- Director New Mountain Capital, L.L.C. disposed of $1,944,593,908 worth of shares (135,985,588 units at $14.30) (SEC Form 4)
- Director Dill David M returned $708,165 worth of shares to the company (49,522 units at $14.30), closing all direct ownership in the company (SEC Form 4)
- Director Henneman John B Iii returned $1,255,040 worth of shares to the company (87,765 units at $14.30), closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Ashdown Clay
- SEC Form 4 filed by Director Wexler Erik G.
- SEC Form 4 filed by Director Nakis Dominic
- Director Bundy Scanlan Agnes returned $472,100 worth of shares to the company (33,014 units at $14.30), closing all direct ownership in the company (SEC Form 4)
- Director Flanagan Joseph Gerard was granted 98,238 shares and returned $49,840,920 worth of shares to the company (3,485,379 units at $14.30), closing all direct ownership in the company (SEC Form 4)
- President Sparby John M. was granted 332,323 shares and returned $9,154,731 worth of shares to the company (640,191 units at $14.30), closing all direct ownership in the company (SEC Form 4)